Oragenics Q2 net loss widens 11.3% to $2.53 million year over year
OGEN•R&D and G&A costs increase
R&D spend more than doubled to $1.18 million, driven by higher external regulatory and clinical consulting for ONP-002.
G&A expense rose 11.97% to $1.42 million, reflecting about $405,000 in higher patent-related costs.
Cash position and clinical update
Cash and cash equivalents totaled $3.9 million at June 30, 2026.
ONP-002 Phase IIa in Australia enrolled 9 participants with no serious adverse events.
Quarterly loss widens as expenses rise
Oragenics posted a GAAP net loss of $2.53 million, widening 11.3% year over year.
Operating loss widened to $2.59 million as total operating expenses climbed 51.24% to $2.59 million.
